Gloves removed as Xerox fight for HP heats up

HP is taking action against Xerox’s attampt at a takeover while a bunch of shareholders are starting to take action against HP’s board.

HP will today explain why a takeover by, or merger with Xerox is bad for its shareholders, along with publication of first quarter results aiming to show that its reorganisation is on the right track.

If that is not sufficient to keep shareholders comfortable, the company last week announced a poison pill defence against an unwanted takeover from any third party, in this case Xerox. Under this plan, HP can issue new shares as soon as any shareholder accumulates more than 20% of its stock. This will immediately dilute that holding, making it impractical for any bidder to build a knock out stake without the agreement of the HP board. And as that board is not talking to Xerox, that is most unlikely at this stage.

The tactics have been employed in the US to prevent hostile takeovers for more than 30 years and were used by Netflix in 2012 to stop an unsolicited bid from Carl Icahn, the driving force behind Xerox and owner of around 4% of HP’s shares.

Xerox has retorted that HP‘s move is because “our bid is receiving overwhelming support from shareholders”. This is likely to be put to the test in March when the $24 a share offer is sent to shareholders.

However. success is likely to be its best defence. Xerox’s revenues are in decline and while it has banked money from the sale of its 25% stake in FujiXerox, it has lost direct access to growing Asian markets. HP‘s board chairman Chip Bergh has defended the poison pill tactic as a move to ensure that HP shareholders are not railroaded into a deal.

“We believe it is essential that HP shareholders have sufficient time and full information when considering any tender offer that Xerox may commence” adding that HP is “very concerned about Xerox’s aggressive and rushed tactics, and any process that is not based on full information is a threat to our shareholders”.

Access to that information would come through exchange of due diligence documentation, something that HP‘s board is resisting.

HP also has another concern to deal with. A Californian legal firm Kessler Topaz Meltzer & Check has filed a class action law suit on behalf of shareholders acquiring shares between 23 February 2017 and 3 October 2019, dates that would include Icahn’s stake. It alleges that a change in strategy towards pricing of ink and printers, which HP said would improve results in the distribution channel because it would have greater visibility over the need for ink and supplies.

This confidence, the suit argues, had the impact of inflating the HP share price even though directors knew at the time that its claims of full visibility were inaccurate. When this was disclosed, the shares dropped, wiping out $690 million of shareholder value.